Genes in the cluster along with the pathways as annotated by experts

	Expert Annotation	
Treatment	Pathway	Regulation Type
RAF1_WT.1	Canonical MAPK	Activator
BRAF_WT.1	Canonical MAPK	Activator
BRAF_WT.2	Canonical MAPK	Activator
RAF1_WT.2	Canonical MAPK	Activator
MOS_WT.1	MAPK	Activator
MOS_WT.2	MAPK	Activator

How similar is this cluster to the other clusters?



Top 5 genes negatively correlated to the cluster

	Expert Annotation			
Treatment	Pathway	Regulation Type	Mean Correlation	Standard Deviation
RBPJ_WT.1	NOTCH	Activator	-0.60	0.07
ERN1_WT.1	Canonical ER Stress/UPR	Activator	-0.55	0.06
XBP1_WT.1	Canonical ER Stress/UPR	Activator	-0.51	0.09
RBPJ_WT.2	NOTCH	Activator	-0.49	0.10
YAP1_WT.3	Canonical Hippo	Inhibitor	-0.48	0.11

What groups of morphological features are distinguishing in the cluster relative to the untreated samples? (maximum of absolute m-score for the features belonging to the same category; m-score defined as median of a feature z-score across genes in the cluster) Black means no feature is available in the category



Which individual morphological features are distinguishing in the cluster relative to the untreated samples? Blue/Red means the feature has a positive/negative z-score. Size is proportional to the z-score value.



How strongly are genes within the cluster correlated?



Plate : 41744 - Genes in the Cluster (Channels are sorted based on their dominance in the grid plot)



Compound IDs and common names (where available); blue/red colored box means the matching compound is positively/negatively correlated with the cluster	Chemical structure	Mean pairwise replicates correlation of the compound signature (95th DMSO replicate correlation is 0.54)	Mean ± standard deviation correlation between compound and each gene in cluster; Tables contain data for individual genes	Mean compound rank when scored against genes in cluster using L1000 profiling ± standard deviation; Tables contain data for individual genes	How similar is the compound signature to the gene clusters in this experiment? (Yellow and red lines correspond to top/bottom 1st and 5th percentile DMSO correlation to all the genes)	Common distinguishing feature categories in the compound and genes in the cluster relative to the untreated samples	Distinguishing individual features for the compound relative to untreated samples. Black means a mismatch; i.e. active (= high z-score in magnitude) in the compound, and either inactive (= small z-score in magnitude) or oppositely active in the gene cluster	Number of PubChem assays in which the compound was tested; assays in which the compound was active are itemized
BRD-K62246028-001-05-6 T5321448 AC1M8FFC MLS000772051 HMS2744H14 ZINC12484090 SMR000376604 PubChem CID : 2485743		0.91 (in 2 replicates)	0.58 ± 0.06 Treatment / Score BRAF_WT.1 0.61 BRAF_WT.2 0.57 MOS_WT.1 0.65 MOS_WT.2 0.57 RAF1_WT.1 0.58 RAF1_WT.2 0.47	NA				Total number of assays tested in: 554. Active in the following assays: • Aqueous Solubility from MLSMR Stock Solutions (AID 1996) • Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts (AID 588335)
BRD-K88156935-001-01-8 PubChem CID : 44494858		0.65 (in 4 replicates)	0.53 ± 0.06 Treatment / Score BRAF_WT.1 0.57 BRAF_WT.2 0.60 MOS_WT.1 0.42 MOS_WT.2 0.49 RAF1_WT.1 0.55 RAF1_WT.2 0.54	0.762 ± 0.118 Treatment / Score BRAF_WT.1 0.702 BRAF_WT.2 0.720 MOS_WT.1 0.955 MOS_WT.2 0.748 RAF1_WT.1 0.833 RAF1_WT.2 0.616				Total number of assays tested in: 53.

BRD-K84480302-001-01-1 PubChem CID : 44485894		0.59 (in 3 replicates)	0.49 ± 0.02 Treatment / Score BRAF.WT.1 0.51 BRAF.WT.2 0.53 MOS.WT.1 0.48 MOS.WT.2 0.48 RAF1.WT.1 0.49 RAF1.WT.2 0.46	0.454 ± 0.336 Treatment / Score BRAF.WT.1 0.121 BRAF.WT.2 0.720 MOS.WT.1 0.717 MOS.WT.2 0.837 RAF1.WT.1 0.138 RAF1.WT.2 0.192				Total number of assays tested in: 48.
BRD-K19608696-001-04-5 MLS001121487 HMS1859H04 HMS2253I17 ZINC6818267 ZINC06818267 SMR000626594 E157-5383 PubChem CID : 16017323		NA (in 1 replicates)	0.48 ± 0.07 Treatment / Score BRAF.WT.1 0.53 BRAF.WT.2 0.53 MOS.WT.1 0.52 MOS.WT.2 0.40 RAF1.WT.1 0.53 RAF1.WT.2 0.37	NA				Total number of assays tested in: 508. Active in the following assays: • qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature (AID 902) • qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature (AID 904) • A screen for compounds that inhibit cell wall-associated teichoic acid synthesis in Staphylococcus aureus (AID 463173) • qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins (AID 485364) • qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project) (AID 588342) • Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA) (AID 651718) • Absorbance-based biochemical high throughput confirmation assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA) (AID 651822)
BRD-K52251545-001-05-2 AC1M5VPS MLS000418615 HMS2531C16 ZINC3270008 SMR000247565 T0510-7581 PubChem CID : 2386323		0.83 (in 4 replicates)	0.47 ± 0.12 Treatment / Score BRAF.WT.1 0.47 BRAF.WT.2 0.58 MOS.WT.1 0.30 MOS.WT.2 0.35 RAF1.WT.1 0.55 RAF1.WT.2 0.56	NA				Total number of assays tested in: 629. Active in the following assays: • Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 (AID 1479) • Antagonist of Human D 1 Dopamine Receptor: qHTS (AID 504652) • High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set (AID 588497)
BRD-K04148681-001-05-3 ZINC00533866 AC1LD9MR MLS000040989 HMS2445P16 ZINC533866 STL237632 SMR000044205 PubChem CID : 663511		0.56 (in 3 replicates)	0.46 ± 0.07 Treatment / Score BRAF.WT.1 0.51 BRAF.WT.2 0.56 MOS.WT.1 0.41 MOS.WT.2 0.37 RAF1.WT.1 0.50 RAF1.WT.2 0.45	NA				Total number of assays tested in: 774. Active in the following assays: • qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region (AID 589) • qHTS Assay for Spectroscopic Profiling in A350 Spectral Region (AID 590) • Cell signaling CRE-BLA (Fsk stim) (AID 662) • Profiling the NIH Molecular Libraries Small Molecule Repository: Autofluorescence at 339/460 nm (AID 709) • qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4 (AID 893) • Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation (AID 504834) • Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts (AID 588335) • Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis (AID 588726) • Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease (AID 624483) • Fluorescence-based biochemical high throughput confirmation assay for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis (AID 651616) • qHTS Assay for Activators of ClpP (AID 651965) • Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Fluroescence-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) assay to identify assay artifacts (AID 652141) • qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT (AID 686978) • qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT (AID 686979)
BRD-K29290722-001-01-4 PubChem CID : 54618609		0.66 (in 4 replicates)	0.46 ± 0.10 Treatment / Score BRAF.WT.1 0.47 BRAF.WT.2 0.55 MOS.WT.1 0.30 MOS.WT.2 0.40 RAF1.WT.1 0.51 RAF1.WT.2 0.55	0.428 ± 0.330 Treatment / Score BRAF.WT.1 0.702 BRAF.WT.2 0.720 MOS.WT.1 0.215 MOS.WT.2 0.748 RAF1.WT.1 0.152 RAF1.WT.2 0.029				Total number of assays tested in: 23. Active in the following assays: • Small molecule inhibitors of miR122 Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity (AID 623901) • Small molecule inhibitors of miR122 Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_Dose_CherryPick_Activity (AID 651956)
BRD-K97424736-001-06-9 ZINC00366916 AC1LHJBH MLS001178679 HMS2845M21 ZINC366916 SMR000477411 PubChem CID : 838857		0.57 (in 2 replicates)	0.45 ± 0.09 Treatment / Score BRAF.WT.1 0.49 BRAF.WT.2 0.58 MOS.WT.1 0.32 MOS.WT.2 0.37 RAF1.WT.1 0.48 RAF1.WT.2 0.50	NA				Total number of assays tested in: 494. Active in the following assays: • Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin (AID 2314) • Luminescence Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301 (AID 2716)
BRD-K47004627-001-05-4 T5743438 SMR000248963 AC1MB58R MLS000334205 HMS2571M17 ZINC3583291 PubChem CID : 2697826		0.78 (in 4 replicates)	0.45 ± 0.03 Treatment / Score BRAF.WT.1 0.46 BRAF.WT.2 0.48 MOS.WT.1 0.39 MOS.WT.2 0.46 RAF1.WT.1 0.44 RAF1.WT.2 0.45	NA				Total number of assays tested in: 625. Active in the following assays: • Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells (AID 2717) • Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4) (AID 463111) • A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (AID 624296) • qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) (AID 624417)

BRD-K33721685-001-06-6
264256-44-2
ZINC00124082
AC1MCK7M
MLS000834970
CTK4F7868
HMS566C02
HMS2799M21
ZINC124082
SPB05238
HE019138
SMR000461586
ZB004280
DB-067628
KB-186434
3B3-057429
PubChem CID : 2745738

NA (in 1 replicates)

0.45 ± 0.05

Treatment	Score
BRAF.WT.1	0.51
BRAF.WT.2	0.49
MOS.WT.1	0.38
MOS.WT.2	0.40
RAF1.WT.1	0.44
RAF1.WT.2	0.46

NA







Total number of assays tested in: 585. Active in the following assays:

- Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation (AID 1321)
- Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin (AID 2314)
- A qHTS for Small Molecule Inhibitors of Shiga Toxin (AID 2315)
- HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8) (AID 2540)
- uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6) (AID 2599)
- uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7) (AID 434973)
- qHTS Assay for Rab9 Promoter Activators (AID 485297)
- qHTS Assay for NPC1 Promoter Activators (AID 485313)
- Single concentration confirmation of uHTS for inhibitors of Sentrin-specific protease 8 (SENP8) using a Luminescent assay (AID 488912)
- Single concentration confirmation of uHTS for inhibitors of Sentrin-specific protease 6 (SENP6) using a Luminescent assay (AID 488915)
- Single concentration confirmation of uHTS for inhibitors of Sentrin-specific protease 7 (SENP7) using a Luminescent assay (AID 488917)
- Single concentration confirmation of inhibitors of Sentrin-specific proteases (SENPs) using a Caspase-3 Selectivity assay (AID 488918)
- Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity (AID 493131)
- Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1) (AID 504766)
- qHTS for inhibitors of binding or entry into cells for Marburg Virus (AID 540276)
- qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project) (AID 588342)
- uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay (AID 588850)
- uHTS identification of Caspase-8 TRAIL sensitizers in a luminescence assay (AID 624354)
- Single concentration confirmation of Caspase-8 TRAIL sensitizer hits in a luminescence panel assay (AID 651596)
- Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12) (AID 652067)
- Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12) (AID 652126)
- Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12). (AID 687014)
- Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition (AID 720647)
- Luminescence-based cell-based high throughput confirmation assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12). (AID 743050)
- Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition Measured in Cell-Based System Using Plate Reader - 7011-01_Antagonist_Dose_CherryPick_Activity_Set2 (AID 743343)
- LGR2:Counterscreen with MC4R Measured in Cell-Based System Using Plate Reader - 7011-02_Antagonist_Dose_CherryPick_Activity (AID 743444)

BRD-K32797868-001-01-7
PubChem CID : 54641357



NA (in 1 replicates)

-0.59 ± 0.05

Treatment	Score
BRAF.WT.1	-0.62
BRAF.WT.2	-0.66
MOS.WT.1	-0.55
MOS.WT.2	-0.51
RAF1.WT.1	-0.63
RAF1.WT.2	-0.59

NA







Total number of assays tested in: 43.

BRD-K24873600-001-01-9
PubChem CID : 54641067

NA (in 1 replicates)

-0.59 ± 0.06

Treatment	Score
BRAF.WT.1	-0.62
BRAF.WT.2	-0.68
MOS.WT.1	-0.52
MOS.WT.2	-0.53
RAF1.WT.1	-0.62
RAF1.WT.2	-0.58

NA

Total number of assays tested in: 38.

BRD-K76988892-001-01-9
PubChem CID : 54646031

NA (in 1 replicates)

-0.59 ± 0.03

Treatment	Score
BRAF.WT.1	-0.58
BRAF.WT.2	-0.63
MOS.WT.1	-0.58
MOS.WT.2	-0.55
RAF1.WT.1	-0.62
RAF1.WT.2	-0.57

0.245 ± 0.100

Treatment	Score
BRAF.WT.1	0.298
BRAF.WT.2	0.280
MOS.WT.1	0.357
MOS.WT.2	0.252
RAF1.WT.1	0.065
RAF1.WT.2	0.219

Total number of assays tested in: 41.

BRD-K41585006-001-05-9
F0526-2250
MLS000696916
HMS2246B17
ZINC8683902
ZINC08683902
SMR000237340
PubChem CID : 12005862



NA (in 1 replicates)

-0.58 ± 0.04

Treatment	Score
BRAF.WT.1	-0.59
BRAF.WT.2	-0.61
MOS.WT.1	-0.52
MOS.WT.2	-0.60
RAF1.WT.1	-0.62
RAF1.WT.2	-0.57

NA







Total number of assays tested in: 650. Active in the following assays:

- qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase) (AID 894)
- qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1) (AID 1030)
- HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay. (AID 1209)
- qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase) (AID 1490)
- Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR) (AID 2796)
- Luminescence-based cell-based high throughput confirmation assay for activators of the Aryl Hydrocarbon Receptor (AHR) (AID 2845)
- Counterscreen for activators of the Aryl Hydrocarbon Receptor (AHR): luminescence-based cell-based high throughput screening assay to identify activators of the Pregnane X Receptor (PXR) (AID 434939)
- qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a (AID 504332)
- uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay (AID 504690)
- Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1) (AID 588852)
- qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation in Primary Screen (AID 602199)
- qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation using a Fluorescein Assay (AID 602200)
- qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation using a Texas Red Assay (AID 602201)
- qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen (AID 720504)

BRD-K40843157-001-04-3
AC1MDOY0
MLS000860671
HMS1525F13
HMS2803K07
HTS08987
ZINC13658631
IDI1 032113
SMR000458755
PubChem CID : 2814542



NA (in 1 replicates)

-0.58 ± 0.03

Treatment	Score
BRAF.WT.1	-0.61
BRAF.WT.2	-0.62
MOS.WT.1	-0.54
MOS.WT.2	-0.57
RAF1.WT.1	-0.59
RAF1.WT.2	-0.57

NA







Total number of assays tested in: 582. Active in the following assays:

- QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1). (AID 1906)
- Aqueous Solubility from MLSMR Stock Solutions (AID 1996)
- HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS (AID 485317)
- qHTS Assay for Inhibitors of JMJD2A-Tudor Domain (AID 504339)

BRD-K16172779-001-01-1
PubChem CID : 54631934



0.75 (in 4 replicates)

-0.58 ± 0.06

Treatment	Score
BRAF.WT.1	-0.63
BRAF.WT.2	-0.64
MOS.WT.1	-0.51
MOS.WT.2	-0.53
RAF1.WT.1	-0.61
RAF1.WT.2	-0.56

0.352 ± 0.277

Treatment	Score
BRAF.WT.1	0.082
BRAF.WT.2	0.263
MOS.WT.1	0.882
MOS.WT.2	0.252
RAF1.WT.1	0.250
RAF1.WT.2	0.384







Total number of assays tested in: 39. Active in the following assays:

- Inhibition of T.cruzi proliferation in culture Measured in Cell-Based System Using Plate Reader - 2138-01_Inhibitor_SinglePoint_HTS_Activity (AID 624255)

BRD-K86621086-001-01-0
PubChem CID : 44494594

0.80 (in 4 replicates)

-0.57 ± 0.08

Treatment	Score
BRAF.WT.1	-0.62
BRAF.WT.2	-0.67
MOS.WT.1	-0.46
MOS.WT.2	-0.49
RAF1.WT.1	-0.61
RAF1.WT.2	-0.58

NA







Total number of assays tested in: 50. Active in the following assays:

- HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity (AID 651654)

BRD-K86846131-001-01-8
PubChem CID : 54645940



NA (in 1 replicates)

-0.56 ± 0.07

Treatment	Score
BRAF.WT.1	-0.55
BRAF.WT.2	-0.67
MOS.WT.1	-0.47
MOS.WT.2	-0.51
RAF1.WT.1	-0.58
RAF1.WT.2	-0.61

0.473 ± 0.288

Treatment	Score
BRAF.WT.1	0.918
BRAF.WT.2	0.752
MOS.WT.1	0.343
MOS.WT.2	0.252
RAF1.WT.1	0.250
RAF1.WT.2	0.323







Total number of assays tested in: 43.

BRD-K42959654-001-01-9
PubChem CID : 54646040



NA (in 1 replicates)

-0.56 ± 0.04

Treatment	Score
BRAF.WT.1	-0.57
BRAF.WT.2	-0.61
MOS.WT.1	-0.53
MOS.WT.2	-0.53
RAF1.WT.1	-0.59
RAF1.WT.2	-0.52

0.303 ± 0.219

Treatment	Score
BRAF.WT.1	0.708
BRAF.WT.2	0.280
MOS.WT.1	0.288
MOS.WT.2	0.252
RAF1.WT.1	0.250
RAF1.WT.2	0.038







Total number of assays tested in: 42.

BRD-K17923226-001-01-5
PubChem CID : 54619100



0.77 (in 4 replicates)

-0.56 ± 0.10

Treatment	Score
BRAF_WT.1	-0.59
BRAF_WT.2	-0.65
MOS_WT.1	-0.39
MOS_WT.2	-0.49
RAF1_WT.1	-0.62
RAF1_WT.2	-0.61

0.511 ± 0.303

Treatment	Score
BRAF_WT.1	0.882
BRAF_WT.2	0.280
MOS_WT.1	0.357
MOS_WT.2	0.252
RAF1_WT.1	0.913
RAF1_WT.2	0.384







Total number of assays tested in: 38.
Active in the following assays:

- MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5 (AID 652115)
- Plasmodium falciparum Dd2 Sybr green parasite growth Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2153-01_Inhibitor_Dose_DryPowder_Activity (AID 1159566)
- Plasmodium falciparum Dd2 Sybr green parasite growth Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2153-05_Inhibitor_Dose_CherryPick_Activity (AID 1159567)
- HepG2 cytotoxicity counterscreen Measured in Cell-Based System Using Plate Reader - 2153-03_Inhibitor_Dose_DryPowder_Activity (AID 1159569)
- Plasmodium falciparum 3D7-ScDHODH Sybr green parasite growth Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2153-02_Inhibitor_Dose_DryPowder_Activity (AID 1159570)
- Plasmodium falciparum PfNITD609-resistant ATP4 D1247Y Sybr green parasite growth Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2153-11_Inhibitor_Dose_DryPowder_Activity (AID 1159571)
- HepG2 cytotoxicity counterscreen Measured in Cell-Based System Using Plate Reader - 2153-03_Inhibitor_Dose_CherryPick_Activity (AID 1159577)